We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Ruairi J Mackenzie

Ruairi J Mackenzie

Senior Science Writer

Contact Us

Ruairi started with Technology Networks in January 2018 after completing an undergraduate degree in neuroscience at the University of Edinburgh and a master’s degree in clinical neuroscience from the University of Cambridge. As senior science writer, Ruairi covers a range of scientific news and articles, with a focus on the complexities and curiosities of the brain. Ruairi also looks after search engine optimization (SEO) efforts on Technology Networks and created the site’s podcast, Opinionated Science, in 2020.


Latest Content
The Sound of Silence: What Happens When Our Brains Imagine Music?
News

The Sound of Silence: What Happens When Our Brains Imagine Music?

In a pair of new studies, researchers have shown how our brains continue to activate in response to music, even when listening to gaps between notes and when imagining music without sound.

Opinionated Science Episode 32:  Debunking the "Hygiene Hypothesis" and Psychedelic Brain Changes
Podcast

Opinionated Science Episode 32: Debunking the "Hygiene Hypothesis" and Psychedelic Brain Changes

On this episode, the team take a look at a new study that suggests people's interpretation of the "Hygiene Hypothesis" - that early exposure to some microorganisms protects against allergic disease - might be in need of a cleanup. They also detail some findings on the psychedelic drug psilocybin and its effects on the connections of the mammalian brain. Not to be missed!
Treating Addiction With Psychedelics: An Interview With Professor David Nutt and Anthony Tennyson, Awakn Life Sciences
Video

Treating Addiction With Psychedelics: An Interview With Professor David Nutt and Anthony Tennyson, Awakn Life Sciences

Psychedelics are being explored for a myriad of neurological and psychiatric conditions. In this video, Technology Networks speak with Professor David Nutt and Anthony Tennyson from Awakn Life Sciences, a Toronto-based company who focus on the use of psychedelics to treat addiction.

Could COVID-19 Usher in a Digital Future for Healthcare?
Article

Could COVID-19 Usher in a Digital Future for Healthcare?

Over the last 18 months, the UK National Health Service (NHS) has been hit hard by the COVID-19 pandemic, with nearly 130,000 deaths from COVID-19 recorded. Could a more digitized, data-centric NHS have saved lives? A new study examining how patients were treated over the first wave of the pandemic has shown how machine learning-based methods could transform how standard NHS care is conducted.
Single Dose of Psychedelic Compound Psilocybin Can Remodel Connections in the Brain
News

Single Dose of Psychedelic Compound Psilocybin Can Remodel Connections in the Brain

Psilocybin, a psychedelic compound that can be derived from over 200 species of mushroom, can remodel connections in the mouse brain. That is the conclusion of a new study that examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.
Opinionated Science Episode 31: Night Owls, Inflatable Implants and Twins' Trauma
Podcast

Opinionated Science Episode 31: Night Owls, Inflatable Implants and Twins' Trauma

How does your circadian clock affect your personality? Why are inflatable implants being considered for back pain? How are migraine and PTSD in identical twins linked? All these questions, and more will be answered on this week's Opinionated Science!
Earliest Strain of Bubonic Plague Bacteria Identified in Neolithic Site
News

Earliest Strain of Bubonic Plague Bacteria Identified in Neolithic Site

Researchers have identified a strain of the bacteria behind the Black Plague in the remains of a neolithic hunter-gatherer who died 5,000 years ago.
Inflatable Spinal Implant Could Help Relieve Chronic Back Pain
News

Inflatable Spinal Implant Could Help Relieve Chronic Back Pain

An inflation innovation could provide an easy way for patients with chronic pain to access an effective therapy that bypasses painkilling opioid drugs.
Monoclonal Antibody Drugs Fail To Improve Alzheimer's Disease Symptoms
News

Monoclonal Antibody Drugs Fail To Improve Alzheimer's Disease Symptoms

The investigational drugs gantenerumab and solanezumab – both monoclonal antibody (mAb) therapeutics – failed to slow cognitive decline in patients with dominantly inherited Alzheimer’s disease (DIAD), a new trial has found.
Opinionated Science Episode 30: Psychedelics: A Trip Through Psilocybin and MDMA Research
Podcast

Opinionated Science Episode 30: Psychedelics: A Trip Through Psilocybin and MDMA Research

On this week’s Opinionated Science, the team take a look at the growing potential of psychedelic medicine. In this episode, we take a deep dive into four leading psychedelic compounds: psilocybin, MDMA, ketamine and DMT.

Advertisement